Amedica (AMDA) and Neovasc (NVCN) Financial Survey

Amedica (NASDAQ:AMDA) and Neovasc (NASDAQ:NVCN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

3.7% of Amedica shares are owned by institutional investors. 0.9% of Amedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Amedica and Neovasc, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedica 0 2 0 0 2.00
Neovasc 0 0 2 0 3.00

Neovasc has a consensus target price of $12,500.00, suggesting a potential upside of 634,417.77%. Given Neovasc’s stronger consensus rating and higher possible upside, analysts clearly believe Neovasc is more favorable than Amedica.

Profitability

This table compares Amedica and Neovasc’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amedica -139.62% -148.60% -67.83%
Neovasc -3,427.42% N/A -79.39%

Earnings and Valuation

This table compares Amedica and Neovasc’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amedica $11.23 million 0.34 -$9.32 million ($3.13) -0.10
Neovasc $5.39 million 7.11 -$22.90 million ($37.00) -0.05

Amedica has higher revenue and earnings than Neovasc. Amedica is trading at a lower price-to-earnings ratio than Neovasc, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Amedica has a beta of -1.24, suggesting that its share price is 224% less volatile than the S&P 500. Comparatively, Neovasc has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

About Amedica

Amedica Corporation, a biomaterial company, develops, manufactures, and commercializes a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. The company offers silicon nitride implants to surgeons and hospitals for use in cervical and thoracolumbar spine surgery under the Valeo brand. It also provides a line of non-silicon nitride spinal fixation products to address spinal deformity and degenerative conditions. The company markets and sells its products directly; and through a network of independent sales distributors, as well original equipment manufacturer and private label partnerships. Amedica Corporation was founded in 1996 and is headquartered in Salt Lake City, Utah.

About Neovasc

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply